Precision BioSciences doses first patient in CAR T cell therapy trial
Category: #health  By Nikita Chaurasia  Date: 2019-04-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Precision BioSciences doses first patient in CAR T cell therapy trial
  • Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm
     
  • The company believes that the patient dosed in the trial is also the first US-based clinical trial to assess an allogeneic CAR T cell therapy for NHL

The US-based genome editing firm Precision BioSciences has reportedly announced that it has successfully administered the dosage of its very first gene-edited allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate, PBCAR0191, in the Phase 1/2a clinical trial. As per trusted sources, PBCAR0191 is developed from T cells derived from donors which are then altered by utilizing the ARCUS genome editing technology of Precision.

Reportedly, the alterations are designed to create CAR T cells which specifically distinguish CD19 – a significant target in several B-cell cancers – to prevent graft-versus-host ailment. According to a press release by Precision BioSciences, the CAR T cell is being assessed in adult patients with relapsed or refractory non-Hodgkin lymphoma or as an off-the-shelf cell therapy.

The company believes that the patient dosed in the trial is also the first US-based clinical trial to assess an allogeneic CAR T cell therapy for NHL.  This open label, multi-center study of PBCAR0191 is anticipated to register a minimum of 80 patients and numerous dose level of PBCAR0191 would be investigated.

According to a press release by Precision BioSciences, the clinical sites include MD Anderson Cancer Center, Dana-Farber Cancer Institute, and Moffit Cancer Center, and City of Hope. Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm.

For the record, the basic goal of the trial is to assess the safety of PBCAR0191 and decide upon the maximum tolerated dose. The secondary goal is to assess the anti-tumor activity of PBCAR0191.

As per reliable sources, the outcomes of the trail would be collected for up to one year.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
By Nikita Chaurasia

Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with TnMUC1 (Tn/STn glycoform of mucin 1) CAR-T (chimeric a...

Hyundai and Uber team up to develop all-electric flying taxis
Hyundai and Uber team up to develop all-electric flying taxis
By Nikita Chaurasia

In the midst of technological advancements increasing at a commendable pace, Uber’s flying taxi initiative seems to be edging closer to reality – the reality of establishing flying cars in the near future. The ride-hailing giant has appar...

BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
By Nikita Chaurasia

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical firm leveraging artificial intelligence approaches to advance the next wave of medicines in immuno-oncology and neuroscience, has reportedly announced the initiation of its SERENITY progr...